Key result
Wearable cardioverter-defibrillators terminate ventricular arrhythmias with ~95% first-shock success in at-risk patients.
Answers are grounded in this paper and cite their sources.
The wearable cardioverter-defibrillator is a safe and effective option for terminating ventricular tachyarrhythmias in patients at risk for sudden cardiac death.
The wearable cardioverter-defibrillator (WCD) consists of a garment containing 3 self-gelling defibrillation patch electrodes, 2 on the back and 1 in the front, and 4 non-adhesive ECG electrodes connected to a monitoring unit (Figure 1). Worn around the chest like a vest, the WCD provides continuous ECG monitoring and automatically delivers up to 5 posterior-anterior defibrillation shocks per ventricular arrhythmia (VA) episode. The WCD proved to be both safe and effective in terminating ventricular tachyarrhythmia in various patient cohorts with primary or secondary prevention indication for sudden cardiac death. The first shock effectiveness varies from 91% in the earlier first-in-human studies to 100% in selected patients at-risk. The device is also able to transmit data via telemonitoring concerning arrhythmia and shock discharge, but also information on therapy compliance/adherence to wear the device. Further clinical information as daily heart rate, step count or cardiac acoustic biomarkers are collected that can potentially assist to monitor heart failure patients.
No takes yet. Share an insight, caveat, or question.
Erath et al. (2023) conducted a review in Risk of sudden cardiac death. Wearable cardioverter-defibrillator (WCD) was evaluated. The wearable cardioverter-defibrillator safely and effectively terminates ventricular tachyarrhythmias, demonstrating a first shock success rate ranging from 91% to 100% in at-risk patient cohorts.
Synapse has enriched 10 related papers. Consider them for comparative context: